Biologic response modifiers in the therapy of metastatic renal cell carcinoma
Quesada, J.R.
Seminars in Oncology 15(4): 396-407
1988
ISSN/ISBN: 0093-7754 PMID: 2457256 Document Number: 310941
Document emailed within 1 workday
Related Documents
Muss, H.B. 1988: The role of biological response modifiers in metastatic renal cell carcinoma Seminars in Oncology 15(5 Suppl 5: 30-34Quesada, J.R. 1989: Biologic response modifiers in cancer therapy: a review Texas Medicine 85(11): 42-47
Brown, T.D. 1989: Biologic response modifiers: understanding biologic systems Texas Medicine 85(11): 4-5
Brown, T.D. 1989: Biologic response modifiers: understanding biologic systems Texas Medicine 85(11): 4-5
Dutcher, J.P. 2011: High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard Oncology 25(5): 427-428
Markenson, J. 2007: Safety and efficacy of the biologic response modifiers American Journal of Orthopedics 36(3 Suppl): 15-19
Cutuli, B.F.; Methlin, A.; Teissier, E.; Schumacher, C.; Jung, G.M. 1990: Radiation therapy in the treatment of metastatic renal-cell carcinoma Progress in Clinical and Biological Research 348: 179-186
Yokota, S. 2007: Biologic response modifiers for juvenile idiopathic arthritis Nihon Rinsho. Japanese Journal of Clinical Medicine 65(7): 1331-1335
Borden, E.C.; Hawkins, M.J. 1986: Biologic response modifiers as adjuncts to other therapeutic modalities Seminars in Oncology 13(2): 144-152
Nakano, E. 1992: Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma Hinyokika Kiyo. Acta Urologica Japonica 38(11): 1305-1309
Lee, D.S.; White, D.E.; Hurst, R.; Rosenberg, S.A.; Yang, J.C. 1998: Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy Cancer Journal From Scientific American 4(2): 86-93
Hall, N.R.; McGillis, J.P.; Spangelo, B.L.; Goldstein, A.L. 1985: Evidence that thymosins and other biologic response modifiers can function as neuroactive immunotransmitters Journal of Immunology 135(2 Suppl): 806s-811s
Hofmockel, G.; Wirth, M.P.; Heimbach, D.; Frohmüller, H.G. 1993: Results of low dosage cyclic interferon-gamma therapy of metastatic renal cell carcinoma Der Urologe. Ausg. a 32(4): 290-294
Katakkar, S.B.; Franks, C.R. 1978: Chemo-hormonal therapy for metastatic renal cell carcinoma with adriamycin, hydroxyurea, vinblastine, and medroxyprogesterone acetate Cancer Treatment Reports 62(9): 1379-1380
2015: Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC) Annals of the Academy of Medicine Singapore 44(10): 406-414
Lauerová, L.; Dusek, L.; Simícková, M.; Rovný, F.; Spurný, V.; Rovný, A.; Slampa, P.; Zaloudík, J.; Rejthar, A.; Wotke, J.; Kovarík, J. 1999: Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy Neoplasma 46(3): 141-149
Sarma, D.P.; Wang, J.F.; McAllister, M.V.; Wang, B.; Shehan, J.M. 2008: Possible implantation carcinoma of the scalp following craniotomy for metastatic renal cell carcinoma Dermatology Online Journal 14(6): 20
Coşkun, F.; Cetinkaya, M.; Cengiz, O.; Adsan, O.; Kulaçoğlu, S.; Eroğlu, A. 1995: Metastatic carcinoma of the gallbladder due to renal cell carcinoma in the ectopic kidney Acta Chirurgica Belgica 95(1): 56-58
Iurin, A.G.; Koval'skiĭ, G.B. 2009: Analysis of survival rates in patients and prognostic models in non-metastatic clear-cell renal cell carcinoma Arkhiv Patologii 71(6): 15-20
He, C.; Qin, C.; Xu, T.; Yuan, Y.; Liu, Z.; Sheng, Z.; Hu, F.; Dun, Y.; Wang, X. 2015: Expression of glycoprotein non-metastatic melanoma protein B in clear-cell renal cell carcinoma and clinical implication thereof Zhonghua Yi Xue Za Zhi 95(30): 2455-2458